Poulton Jeffrey V. — SEC Form 4 filings
SEC reporting owner CIK 1782962. 18 Form 4 filings on record with FilingPulse; latest filed 2026-06-10.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-20 to 2026-06-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 112 legs across 13 filings — 23,686 shares, $7,760,545 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 2,242 shares @ $310.08 ($695,201) in ALNYLAM PHARMACEUTICALS, INC., filed 2026-02-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | 15 | — | 112 legs · 23,686 sh · $7,760,545 | 21 |
| CervoMed Inc. (CRVO) | Director | 3 | — | — | 3 |
Form 4 filings — Poulton Jeffrey V.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-10 | 4 | CervoMed Inc. (CRVO) | Grant/award (A): 8,150 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 114 @ $319.03 · Sale (S): 109 @ $320.01 · Sale (S): 230 @ $320.81 · Sale (S): 309 @ $321.82 · Sale (S): 374 @ $323.01 · Sale (S): 818 @ $323.84 · +2 more | EDGAR |
| 2026-03-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,769 @ $0 · Sale (S): 65 @ $323.62 · Sale (S): 124 @ $324.65 · Sale (S): 356 @ $325.63 · Sale (S): 541 @ $326.81 · Sale (S): 454 @ $327.67 · +6 more | EDGAR |
| 2026-03-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Option exercise (M): 1,908 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,579 @ $0 · Sale (S): 2,242 @ $310.08 | EDGAR |
| 2026-01-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 6,193 @ $0 · Sale (S): 72 @ $353.95 · Sale (S): 78 @ $355.16 · Sale (S): 76 @ $356.09 · Sale (S): 176 @ $357.17 · Sale (S): 226 @ $358.18 · +16 more | EDGAR |
| 2025-10-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,108 @ $0 · Grant/award (A): 4,644 @ $0 · Sale (S): 150 @ $446.53 · Sale (S): 73 @ $447.92 · Sale (S): 234 @ $448.77 · Sale (S): 324 @ $449.79 · +8 more | EDGAR |
| 2025-08-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,644 @ $0 · Sale (S): 63 @ $447.98 · Sale (S): 147 @ $449.92 · Sale (S): 63 @ $450.92 · Sale (S): 168 @ $451.99 · Sale (S): 536 @ $452.96 · +3 more | EDGAR |
| 2025-06-25 | 4 | CervoMed Inc. (CRVO) | Grant/award (A): 8,100 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 15,117 @ $0 · Sale (S): 350 @ $242.37 · Sale (S): 382 @ $243.36 · Sale (S): 258 @ $244.41 · Sale (S): 189 @ $245.26 · Sale (S): 77 @ $246.18 · +3 more | EDGAR |
| 2025-03-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Sale (S): 42 @ $236.51 · Sale (S): 34 @ $238.33 · Sale (S): 35 @ $239.18 · Sale (S): 78 @ $240.32 · Sale (S): 127 @ $241.51 · +4 more | EDGAR |
| 2025-02-18 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,109 @ $0 · Sale (S): 217 @ $252.50 · Sale (S): 239 @ $253.37 · Sale (S): 160 @ $254.35 · Sale (S): 68 @ $255.56 · Sale (S): 78 @ $256.29 · +7 more | EDGAR |
| 2024-11-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,434 @ $0 · Sale (S): 30 @ $247.77 · Sale (S): 246 @ $249.60 · Sale (S): 364 @ $250.68 · Sale (S): 945 @ $251.42 · Sale (S): 97 @ $252.27 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,278 @ $0 · Sale (S): 59 @ $221.71 · Sale (S): 13 @ $224.17 · Sale (S): 18 @ $225.55 · Sale (S): 34 @ $226.82 · Sale (S): 129 @ $228.30 · +7 more | EDGAR |
| 2024-06-14 | 4 | CervoMed Inc. (CRVO) | Grant/award (A): 5,750 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 7,741 @ $0 · Grant/award (A): 15,118 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Sale (S): 247 @ $154.54 · Sale (S): 194 @ $155.45 · Sale (S): 115 @ $156.38 · Sale (S): 17 @ $157.30 · Sale (S): 1 @ $158.09 · +1 more | EDGAR |
| 2024-02-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,278 @ $0 · Sale (S): 369 @ $147.50 · Sale (S): 518 @ $148.24 · Sale (S): 120 @ $149.03 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1782962 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →